(Q48728901)

English

Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/22341819

Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/22341819

prostatic hypertrophy

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/22341819

3

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/22341819

Karoly Szepeshazi

6

object named as

Karoly Szepeshazi

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/22341819

4

object named as

Norman L Block

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/22341819

Irving Vidaurre

7

object named as

Irving Vidaurre

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/22341819

10

object named as

Zoltan Rekasi

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/22341819

2

object named as

Luca Szalontay

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/22341819

author name string

Mehrdad Nadji

5

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/22341819

Marta Zarandi

8

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/22341819

Magdolna Kovacs

9

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/22341819

language of work or name

0 references

publication date

17 February 2012

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/22341819

Journal of Urology

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/22341819

187

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/22341819

4

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/22341819

1498-1504

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/22341819

LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JURO.2011.11.081

Androgens and estrogens in benign prostatic hyperplasia: past, present and future

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JURO.2011.11.081

Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JURO.2011.11.081

Cyclooxygenases: structural, cellular, and molecular biology

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JURO.2011.11.081

Antagonists of growth hormone-releasing hormone inhibit the proliferation of human benign prostatic hyperplasia cells

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JURO.2011.11.081

Animal models for benign prostatic hyperplasia

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JURO.2011.11.081

Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JURO.2011.11.081

Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JURO.2011.11.081

Six-transmembrane epithelial antigen of the prostate as an immunotherapeutic target for renal cell and bladder cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JURO.2011.11.081

Antioxidant activity of growth hormone-releasing hormone antagonists in LNCaP human prostate cancer line

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JURO.2011.11.081

Ezetimibe Reduces Enlarged Prostate in an Animal Model of Benign Prostatic Hyperplasia

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JURO.2011.11.081

Il-1 beta-induced post-transition effect of NF-kappaB provides time-dependent wave of signals for initial phase of intrapostatic inflammation

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JURO.2011.11.081

A correlation of endocrine and anticancer effects of some antagonists of GHRH.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JURO.2011.11.081

Effects of the gonadotropin-releasing hormone antagonist ganirelix on normal micturition and prostaglandin E(2)-induced detrusor overactivity in conscious female rats

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JURO.2011.11.081

STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JURO.2011.11.081

Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JURO.2011.11.081

New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JURO.2011.11.081

Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JURO.2011.11.081

Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JURO.2011.11.081

Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JURO.2011.11.081

Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JURO.2011.11.081

Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JURO.2011.11.081

Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JURO.2011.11.081

A potential autocrine pathway for growth hormone releasing hormone (GHRH) and its receptor in human prostate cancer cell lines.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JURO.2011.11.081

Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JURO.2011.11.081

Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JURO.2011.11.081

The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.JURO.2011.11.081

Identifiers

10.1016/J.JURO.2011.11.081

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/22341819

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/22341819

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48728901&oldid=2207895561"